

## Largest Reported 3 Month Drop in HbA1c for a Newly Diagnosed Patient with Type 2 Diabetes

John F. Burd, PhD<sup>1\*</sup>, Francisco Alberto Alvarez Melero, MD<sup>2</sup> and Vivianne Noetzel<sup>1</sup>

<sup>1</sup>Lysulin, Inc., San Diego, California, US.

<sup>2</sup>Saint John's Medical Center, Tijuana, Baja California, US.

### \*Correspondence:

John F. Burd, Lysulin, Inc., San Diego, California, US, E-mail: jburd@jburd.com.

Received: 24 August 2018; Accepted: 19 September 2018

**Citation:** John F. Burd, Alvarez Melero FA, Noetzel V. Largest Reported 3 Month Drop in HbA1c for a Newly Diagnosed Patient with Type 2 Diabetes. *Diabetes Complications*. 2018; 2(3): 1-2.

Diabetes mellitus is a leading cause of morbidity and mortality worldwide [1]. The causes of type-2 diabetes are multi-factorial, and supplements can play an important role on its' incidence, severity and management [2]. Hence studies have frequently focused on dietary components beneficial in the prevention and treatment of diabetes. Recent studies have demonstrated that numerous herbal and nutraceutical products have beneficial effects in patients by improving glucose and lipid metabolism, antioxidant status, disease progression and capillary function [3].

Lysulin™ is a new supplement for people with Type 2 diabetes and prediabetes and those at risk of developing diabetes and metabolic syndrome [4]. Lysulin is a nutritional supplement tablet manufactured in the USA which contains the essential amino acid Lysine, a micronutrient Zinc and Vitamin C as the active ingredients, together with other standard excipients (Lysulin Inc, San Diego, CA) ([www.lysulin.com](http://www.lysulin.com)). The active ingredients in the patent pending Lysulin formulation have all been shown in over 20 years of R&D and clinical studies to lower blood glucose, lower glycated proteins and improve the lipid profile by lowering cholesterol and LDL and raising HDL. Daily use of Lysulin™ may slow or halt the progression of prediabetes to diabetes and slow or halt the progression of diabetes complications by lowering protein glycation.

We wish to report the largest documented three month drop in HbA1c in a newly diagnosed patient with Type 2 diabetes. MR was diagnosed with Type 2 diabetes as a result of an HbA1c of 12.8. He immediately was prescribed 2000 mg Metformin and 2 mg Lisinopril a day. He also started self-treatment with 2 servings a day of Lysulin, a nutritional supplement for people with diabetes and prediabetes.

The following drop in HbA1c was observed:

Time	HbA1c	Test Method	% Drop from Day 0	% of 12.8
Day 0	12.8%	Laboratory	NA	100
4 week	7.9%	A1cNow	4.9	61.7
8 week	5.8%	A1cNow	7.0	45.3
12 week	5.4%	Laboratory	7.4	42.1 (a 57.8% drop)

As seen, a dramatic drop in HbA1c was observed after just one month and by 3 months the HbA1c had dropped from 12.8% down to 5.4%.

Several new double blind, placebo controlled studies are underway and we plan to report on the finding that the drop in HbA1c can be seen in as little as 1 month following treatment with Lysulin and also that the use of continuous glucose monitoring shows improvement in glycemic control is as little as one week following the initiation of use of Lysulin (manuscript in preparation). Such observations may mean that home testing for HbA1c on a monthly basis may lead to more effective diabetes management. This report of a large drop in HbA1c is extraordinary and shows the promise of adding Lysulin to other oral diabetes medicines to achieve outstanding glycemic control.

### References

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. *Diabetes Care*. 27: 1047-1053.
2. Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association.

- 
3. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. *Int J Clin Pract.* 65: 314-322.
  4. Burd J, Lysulin™, a new supplement for Nutritional Support for People with Diabetes and Pre-diabetes (those at risk of developing diabetes). *Diabetes Manag.* 2018; 8: 38-40.